79 results about "Oral emulsion" patented technology

The invention provides a curcumin oral emulsion and injection, wherein the emulsion comprises curcumin, oil, emulsifying agent and water, the injection also contains isotonic agent. The invention also discloses the process for preparing the emulsion and its use in preparing medicaments for treating or preventing tumor, resisting tumor transfer, enhancing curative effects of chemotherapy drugs, reducing side effects of chemotherapy and improving immunity functions for tumor patients.

The invention relates to a coenzyme Q10 oral emulsion and its preparation method, wherein the constituents include coenzyme Q10 0.1-80%, medicinal oil 1-95%, emulsifying agent 0.5-30%, auxiliary emulsifying agent 0-10%, anti-oxidant 0.001-15%, and balancing purified water. The emulsion can be prepared through inversion phase emulsification method, PIT emulsification method, alternative liquid feeding emulsification method, or continuous emulsification method.

The invention relates to a non-finasteride oral preparation and preparation method, specifically which consists of main drug non-finasteride and medicinal findings. Its contents are oily liquid or semi-solid, and it can be made of soft capsules, liquid-filled capsules and oral emulsion. The important contribution of the invention is preparing the steroidal hormone compounds into liquid or semi-solid in agent preparation early period, avoiding occupational hazard caused by dust flying, protecting workers involving in manufacture;In addition, non-finasteride is the combination of lipophilic compounds, oily liquid or semi-solid drugs and supplies, it can increase the drug dissolution rate, improve bioavailability. The application of the invention can improve labor protection, and also can provide better curative effect in clinical application.

The invention provides a method for preparing high-purity beta-elemene from a low-content (over 1 percent) elemene raw material, which simplifies the steps of process operation, improves the production efficiency from an initial raw material to the high-purity beta-elemene, and reduces production cost. Compared with the prior art, the method comprises the following main different points: volatile oil constituents with large polarity is removed from the elemene raw material with the content over 1 percent under the action of silica gel column chromatography; then impurity constituents with small polarity is removed form a residual oil phase by a silver nitrate complexation extraction method and silver nitrate bonded silica gel column chromatography; and finally the beta-elemene with the content of between 95.0 and 99.9 percent is obtained through distillation under reduced pressure or rectification. The raw material medicament can be produced into oral administration preparations such as oral emulsions, capsules and the like, and can also be produced into non-intestinal administration preparations such as emulsion injections, water injections, cutaneous permeable agents, lung spray formulations, suppositories and the like. The experimental method has novel design and concise operating steps, obviously improves the yield, and reduces production cost.

The invention discloses an abiraterone oral emulsion and a preparation method thereof. The preparation comprises an active component, a solubilizer, an emulsifier and an antioxidant; the active component is abiraterone acetate or abiraterone; and the preparation comprises, by weight, 2%-10% of abiraterone acetate or abiraterone, 20%-70% of the solubilizer, 20%-40% of the emulsifier and 0.01%-1% ofthe solubilizer. According to the invention, the drug loading capacity and the stability of the abiraterone oral emulsion are high; and the abiraterone oral emulsion can be spontaneously emulsified to form an emulsion when meeting water. And the formed emulsion is stable; the digestion influence is low; the dissolution of medicines in gastrointestinal tracts is improved; the absorption of the medicines is promoted; and the bioavailability is improved.

A natto kinase oral emulsion is composed of an oil phase and an aqueous phase; wherein the aqueous phase is a natto kinase water solution with a concentration of 100 to 10000 IU / mL; and the oil phase is composed of the following components in percentage by the total weight of the oil phase: 8 to 12% of phosphatide, 4 to 6% of bee wax, 0.4 to 1% of deoxycholic acid, 1.25 to 5% of auxiliary emulsifier, and the balance being oil. The invention also provides a preparation method of the oral emulsion. The oral emulsion can prominently improve the thermal stability and preservation stability of natto kinase, and improve the drug effect of orally-taken natto kinase at the same time. Furthermore, the preparation method has the advantages of simple operation, low production cost, and easiness for large-scale production.

The invention belongs to the technical field of medicines and foods, relates to an enteric-coated microcapsule of an oily medicine or food, a preparation method and application thereof, in particular to the brucea javanica oil enteric-coated microcapsule, the preparation method and application thereof. The preparation method comprises the following steps: adding lecithin and an antioxidant to brucea javanica oil to absorb the oil to porous starch so as to obtain an oily soft material; adding an adhesive to the oily soft material, stirring at a high speed, granulating and then sieving to obtain a core material; and finally placing the core material in a bottom-spraying fluidized bed, and then spraying enteric-coated coating liquid to obtain the enteric-coated microcapsule. The brucea javanica oil enteric-coated microcapsule can conceal stench of the brucea javanica oil, avoid nausea and gastric stimulation, is easier to accept by patients, and has stability better than that of oral emulsion and more stable and regular drug release compared with single capsule; and the brucea javanica oil enteric-coated microcapsule and a further preparation thereof are applicable to treatment of various cancers such as lung cancer, brain metastasis, liver cancer and the like and adjunctive treatment after radiotherapy and chemotherapy.

The invention provides a curcumin oral emulsion and injection, wherein the emulsion comprises curcumin, oil, emulsifying agent and water, the injection also contains isotonic agent. The invention also discloses the process for preparing the emulsion and its use in preparing medicaments for treating or preventing tumor, resisting tumor transfer, enhancing curative effects of chemotherapy drugs, reducing side effects of chemotherapy and improving immunity functions for tumor patients.

The invention aims to disclose an origanum oil oral emulsion and a preparation method of the origanum oil oral emulsion. The origanum oil oral emulsion comprises the following components according to weight percentage of 0.5-10% of origanum oil, 0.5-20% of an emulsifying agent, 0.5-10% of an auxiliary emulsifying agent, 0.01-1% of a preservative, 0.005-0.1% of an antioxidant, and the balance of purified water. Compared with the prior art, the disadvantages that the origanum oil is volatile and instable, has great thrill and is inconvenient to use can be effectively overcome; and the origanum oil oral emulsion has the characteristics of stability, high efficiency, greenness, safety, no drug resistance, no residues and convenience for use; and the aim of the invention is realized.

The invention discloses a xiangsha (Chinese character) oral emulsion for nourishing the stomach, comprising the following components: (i) 60-85% of xiangsha stomach-nourishing soup and 0.5-1.2% of volatile oil, (ii) 1.0-15% of medicinal oil, (iii) 3.0-25% of emulsifier, (iv) 0-10% of auxiliary emulsifying agent, (v) 0.005-1.0% of antioxidant, (vi) 0-1.5% of preservative and the balance of water. The xiangsha oral emulsion for nourishing the stomach is simple in preparation technology, low in production cost, good in stability and high in bioavailability.

The invention belongs to the technical field of oral emulsion preparations, and particularly relates to long-acting composite vitamin oral emulsion for livestock and a preparation method thereof. The emulsion comprises vitamin A, vitamin D, vitamin E, vitamin B, vitamin B2, vitamin B6, vitamin C, non-ionic surface active agents A, non-ionic surface active agents B, soybean lecithin, a solvent, an antioxidant, EDTA-2Na and the balance water for injection. According to the long-acting composite vitamin oral emulsion for the livestock and the preparation method thereof, the particle size of the prepared emulsion ranges from 0.1 micron to 50 microns, the prepared emulsion is prone to being absorbed after the emulsion enters livestock bodies, the acting time is long, clinical administration is convenient, the emulsion is suitable for community administration, and the manpower and the material resources are saved.

The invention relates to a ginkgo flavone liposome oral emulsion formula and a preparation method thereof. In the prepared oral emulsion, a ratio of ginkgo flavone to phospholipid is 0.5-1:5:1. The oral emulsion also comprises vitamin E, cholesterol, sorbitol, beta-cyclodextrin, polyethylene glycol (PEG), and lactose. The ginkgo flavone liposome oral emulsion provided by the invention can endure 30min of heat sterilization treatment under a temperature of 121 DEG C, and has high tolerance against low-pH environments. Therefore, a preparation requirement for large change in stomach and intestinal pH values after oral administration is satisfied. The liposome can be digested and absorbed by human body, such that ginkgo flavone pharmacological effect can be improved.

The invention provides a dipyridamole emulsion which comprises the following components in parts by weight: 1-2.5 parts of dipyridamole, 5-75 parts of emulsifier, 0.1-15 parts of a co-emulsifier, 25-150 parts of oil, 250-500 parts of water, 0.5-1 part of a sweetening agent, 1-2 parts of an aromatic and 0.25-0.5 part of a preservative. The dipyridamole emulsion provided by the invention has the advantages of uniform texture, good stability, improved drug dissolution, easiness in absorption by the human body and high bioavailability. After high-pressure homogenization, the particle size of the emulsion is small in uniform distribution, the emulsion has good stability, the dissolution of dipyridamole is remarkably improved, and the oral bioavailability is enhanced; and flavoring agents such as the sweetening agent and the aromatic also can be added into the emulsion, so that disagreeable tastes of the drug can be effectively covered, and multiple tastes provide multiple options for children. Through a sterilization process, a little or no preservative can be added, so that the quality of the finished product of the emulsion is improved, and the safety of pediatric drugs is further enhanced.

The invention discloses a perilla oil oral emulsion with a lipid-lowering nutritious function, and a preparation method thereof. The invention discloses an oil-in-water type perilla oil oral emulsion and the preparation method thereof. The emulsion takes perilla oil as a main raw material, and is characterized by being prepared through the following components according to proportion: 5 to 50 percent of the perilla oil, 0.5 to 30 percent of an emulgator, 0 to 0.5 percent of a corrigent and the balance of purified water, and emulsification is adopted as the preparation method. Based on the perilla oil, the perilla oil oral emulsion has a delicate flavor and also has an anti-oxidation effect, and an antioxidant and a smell mask are not required to add. Compared with a conventional product, the emulsion provided by the invention is high in perilla oil content, good in taste and convenient to eat, is wide in applicable human populations, and can obtain a better effect under low dosage; the emulsion is relatively good in dispersibility and thermodynamic stability, has low probability of phase splitting and precipitating, is easy to store, simple in process, convenient for large scale production, and has great social value and economic value.

The invention belongs to the technical field of medicine, particularly relates to oil-in-water composite nanometer emulsion loaded with hydrophobic medicine and nutrients and a preparation method thereof. The oil-in-water composite nanometer emulsion is characterized by being obtained by introducing protamine into a protein-polysaccharide covalence grafting emulsion. An emulsion drop is structurally characterized in that an oil drop containing hydrophobic medicine and nutrients is used as an inner core; globulin / protamine is used as an oil-water interface film; polysaccharide / protamine is positioned outside the oil drop so as to maintain the dispersion stability of the oil drop in the water phase and to promote the absorption characteristics. The prepared oil-in-water composite nanometer emulsion can be used as an oral preparation of hydrophobic medicine and nutrients. Compared with the injection preparation of the corresponding medicine, the prepared emulsion has the advantages that the oral administration efficacy can reach 30 to 40 percent of the injection preparation; under the administration condition of reaching the same treatment effect, the prepared oral emulsion has lowertoxicity than the injection preparation; in addition, the administration is more convenient.

The invention discloses an oral emulsion rich in [alpha]-linolenic acid. The oral emulsion is prepared from the following components in percentage by weight: 1-25% of plant oil containing the [alpha]-linolenic acid, 1-25% of an emulsifier, 0.1-20% of adjuvants, 0.001-5% of an antioxidant, 0-1.5% of flavoring agent and the balance of purified water; and the plant oil containing the [alpha]-linolenic acid is extracted from the following components in parts by weight: 20-25 parts of eucommia ulmoides oliver seeds, 10-15 parts of perilla seeds, 10-15 parts of kiwi fruit seeds, 12-17 parts of peony seeds, 10-16 parts of linseed and 7-12 parts of Chinese prickly ash seeds. The invention also discloses a preparation method of the oral emulsion rich in the [alpha]-linolenic acid. The oral emulsion containing the [alpha]-linolenic acid prepared by the invention is stable in ingredient, high in bioavailability, free from toxic and side effects, obvious in curative effect, broad in application to indications and obvious in social and economic values, and bad smell and taste of the oil can be masked.

The invention belongs to the technical field of medicine, and relates to a pulsatilla chinensis total saponin oral emulsion and a preparation method thereof. The emulsion comprises the following components: 0.13%-13.5% of pulsatilla chinensis total saponins, 5%-50% of medicinal oil, 1%-30% of emulsifiers, 0-10% of auxiliary emulsifiers, 0.1%-15% of anti-oxidants, and the balance of purified water. The emulsion can be prepared by methods such as phase inversion emulsification method, PIT emulsification method, alternate liquid feeding emulsification method, ultrasonic wave emulsification method, low-energy emulsification method, micro-fluidization method, and the like. The pulsatilla chinensis total saponins provided by the invention are indissolvable drugs, and have irritation to gastrointestinal tracts. The dispersity of emulsion droplets in the emulsion is great, which facilitates drug absorption and increases bioavailability; the emulsion enables the drugs to be located in oil-water interfacial films or oil drop nuclei, which prevents direct contact of the drugs with gastrointestinal tracts, and thus reduces the gastrointestinal tract irritation of the drugs. The emulsion is a good carrier of pulsatilla chinensis total saponins; the addition of the auxiliary emulsifiers solves the problem of poor stability of common emulsions; when the emulsion is centrifuged at a rotating speed of 4000 r / min for 30 min, no layering phenomenon is caused; the bioavailability is high; and the stability is good.

The invention discloses a pharmaceutical preparation containing rifaximin gel and rifaximin oral emulsion and a preparation method thereof, wherein the gel comprises rifaximin and a gel matrix, the mass ratio of the rifaximin to the gel matrix is (2-80):(5-64), and the gel matrix comprises 2-30 parts by weight of a water-soluble gel matrix and 0.5-2 parts by weight of a modifier; and the rifaximin oral emulsion comprises 1-40 parts by weight of rifaximin, 50-350 parts by weight of an oil phase, 1-300 parts by weight of an emulsifier, and 0-150 parts by weight of a co-emulsifier. In the preparation, on the premise of guaranteeing that the dose of a main drug is appropriate, through the selection of auxiliary materials and preparation methods, rifaximin is prepared into gel or oral emulsion, thereby facilitating the oral administration and absorption of drugs, and achieving relatively high bioavailability. Meanwhile, a newer and better dosage form choice is provided for clinic.

The invention belongs to the technical field of medicines, and in particular relates to a seabuckthorn seed oil oral emulsion. The seabuckthorn seed oil oral emulsion is characterized by being prepared from the following components in percentage by weight: 1-20% of seabuckthorn seed oil, 0.5-30% of emulsifier, 0.1-20% of assistant emulsifier, 0.001-5% of antioxidant, 0-0.5% of corrigent and the balance of purified water. The preparation method is emulsification. Compared with the existing products, the seabuckthorn seed oil oral emulsion has the advantages that dispersibility of drops in emulsion droplet is good, and the superficial area is large and is favorable to the absorption of the seabuckthorn seed oil and exerting of the efficacy, so that the bioavailability is improved and bad odor and taste of oil can be covered. The emulsion prepared is suitable for oral administration. The pharmacodynamic experiment shows that the oral emulsion has better effect as compared with crude oil, and the use dose of the crude oil can be greatly reduced. Compared with chemical medicines, the emulsion provided by the invention is free from toxic and side effect, remarkable in curative effect and wide in adaptation disease, and has great social and economic values.

The invention discloses a pharmaceutical composition and preparation comprising active constituents of aceglutamide and safflower, which can be used for preparing medicaments for treating cardiovascular and cerebrovascular diseases, and can be prepared into tablets, capsules, drop pills, injections, pills, syrups, granules, oral liquids, orally administered turbid liquors or oral emulsions.

In one aspect, the invention relates to a method of making an emulsion composition. The method includes forming a water-in-oil emulsion and adding a galvanic particulate to the water-in-oil emulsion. In another aspect, a water-in oil emulsion is provided. The water-in-oil emulsion includes a water phase emulsified in a continuous oil phase; and a galvanic particulate. The oil-in water emulsion has a yield stress of at least about 20 Pascals (Pa).

The invention discloses oral emulsion containing ganoderma lucidum spore oil and ganoderan and a preparation method and application of the oral emulsion. The oral emulsion comprises, by mass, 1-50% ofthe ganoderma lucidum spore oil, 1-50% of ganoderan, 0.2-10% of an emulsifier, 0-40% of other medicines and food acceptable raw auxiliary materials and 1-97.8% of sterile water. The oral emulsion canbe used for effectively promoting the common absorption of ganoderan and lipid-soluble compounds such as ganoderma triterpenes in the ganoderma lucidum spore oil, and achieves a synergistic effect.

The invention relates to an oral calcium supplement for cow and a preparation procedure of the oral calcium supplement , in particular to a multi-vitamin colloidal calcium emulsion and a preparation procedure thereof. The drug substance of the multi-vitamin colloidal calcium emulsion provided by the invention comprises the following components: 0.1-0.5 parts by weight of vitamin A, 0.1-3 parts by weight of vitamin D3, 0.1-0.5 parts by weight of vitamin E, 5-65 parts by weight of emulsifier, 80-120 parts by weight of calcium gluconate, 0.1-3 parts by weight of vitamin B10, 0.1-3 parts by weight of nicotinamide, 0.01-0.02 parts by weight of butylated hydroxytoluene, 0.05-0.2 parts by weight of EDTA-2Na, 0.5-1.0 parts by weight of sodium benzoate and 0.5-1.0 parts by weight of methylparaben. The raw materials is mixed, emulsified through a high-pressure homogenizer, filtered, filled and capped or sealed to get oral emulsions. The multi-vitamin colloidal calcium emulsion has the advantages of definite curative effect, convenience in use, small stress and low cost.

An orally-taken composite emulsion of Chuanhuning is prepared from Chuanhuning, surfactant as emulsifier, organic solvent as coemulsifier and oil. It has higher biologic utilization rate.

The invention provides a vitamin K1 lyophilized oral emulsion and a preparation method thereof, and relates to the technical field of medicines and medicine manufacture. The emulsion is prepared from the following components in percentage by weight: 0.125-1 percent of vitamin K1, 5 percent of alpha-cyclodextrin, 91.5-92.5 percent of distilled water, 2.5-3.5 percent of medium chain triglyceride, and 0.7 percent of lactose. The vitamin K1 oral bionic emulsion provided by the invention is an orderly single-layer colloid particle shell formed by self-assembly of colloid particles, and is stabilized in the oil-water interface. Compared with an injection, tablets and a traditional emulsion, the vitamin K1 lyophilized oral emulsion has the advantages that a surfactant and an organic solvent which have a sensitization risk do not need to be added in the process, so that adverse reactions are reduced; the preparation method adopting the lyophilization process has the characteristics of stable dynamics and thermodynamics, and the emulsion has good re-dissolubility after 0.1-0.2 percent of NaCl is added; and breast milk is imitated in an all-sided manner from the composition of auxiliaries and preparation and the physicochemical property, so that the new-born specificity of the vitamin K1 lyophilized oral emulsion can be realized.

The invention relates to a non-finasteride oral preparation and preparation method, specifically which consists of main drug non-finasteride and medicinal findings. Its contents are oily liquid or semi-solid, and it can be made of soft capsules, liquid-filled capsules and oral emulsion. The important contribution of the invention is preparing the steroidal hormone compounds into liquid or semi-solid in agent preparation early period, avoiding occupational hazard caused by dust flying, protecting workers involving in manufacture;In addition, non-finasteride is the combination of lipophilic compounds, oily liquid or semi-solid drugs and supplies, it can increase the drug dissolution rate, improve bioavailability. The application of the invention can improve labor protection, and also can provide better curative effect in clinical application.

The invention discloses a preparation method of kiwi fruit seed oil oral emulsion. The kiwi fruit seed oil oral emulsion is characterized by comprising the following raw materials in parts by weight: 25-40 parts of kiwi fruit seed oil, 5-15 parts of modified granulesten, 0.2-0.5 parts of tween-80, 0.5-1 part of sodium alginate, 0.02 parts of vitamin E, 0.3-0.5 parts of xylitol and 42.98-68.98 parts of water. The preparation method of the kiwi fruit seed oil oral emulsion is characterized by comprising the following steps: preparation of oil-phase liquid, preparation of water-phase liquid, vacuum emulsification, high-pressure homogenization, filtering and sub-package. The kiwi fruit seed oil oral emulsion prepared by the method is rich in alpha-linolenic acid. The kiwi fruit seed oil oral emulsion not only effectively keeps various nutritional ingredients and active matter in the kiwi fruit seed oil, but also enhances the diet therapy double functions of the product by adding the nutritional ingredients such as phospholipid, the sodium alginate, the vitamin E and the like. The kiwi fruit seed oil oral emulsion is pure green health-care food which is easy to absorb, fragrant, sweet, tasty, refreshing, nutritional and hygienical.

The invention belongs to the technical field of medicine, and in particular, relates to an orlistat oral emulsion and a preparation method thereof. The orlistat oral emulsion provided by the inventionincludes the following components by the mass percentage: 2-2.6% of orlistat, 0.32-0.38% of an emulsifier, 6-9% of a flavoring agent, 0.7-1.2% of a suspending aid, 0.08-0.12% of potassium sorbate, 0.08-0.12% of an essence, and 86.58-90.82% of purified water. In the orlistat oral emulsion provided by the invention, orlistat is dispersed in water in a form of extremely fine emulsion particles and is released immediately after oral administration, and the orlistat oral emulsion has fast absorption and release by oral administration and high bioavailability. In addition, the quality of the orlistat oral emulsion provided by the invention meets the standard requirements, and the quality is stable.

The invention provides a baicalin oral emulsion and an injection emulsion. The emulsion contains baicalin, oil, an emulsifier and water, and the injection emulsion also contains an isoosmotic adjustment agent and the like.

The invention discloses an anti-cancer ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid 5F oral emulsion and a preparation method thereof. The oral emulsion comprises components in percentage by mass as follows: 5%-45% of an oil phase containing ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid 5F, 5%-45% of a compound of a surfactant and a cosurfactant and the balance of water. Compared with the prior art, the anti-cancer ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid 5F oral emulsion has the benefits as follows: 1, the oral emulsion is high in solubility, convenient to use and low in risk, the reaction condition is mild, water-insoluble ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid 5F is improved to be water-soluble, and the oral emulsion is suitable for being taken orally; and 2, the oral emulsion has good water smoothness, has particle diameter smaller than 50 nm, adopts a controlled release form and has targeting to tumor tissue and good oral bioavailability.